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Autoimmune diseases result from complex and multigenic phenotypes that are affected by a variety of
genetic and environmental or stochastic factors. Many models have been used to demonstrate
autoimmune diseases such as Sjo¨gren’s syndrome (SS). However, it remains unclear as to why speciﬁc
organs such as the salivary or lacrimal glands are targeted by autoimmune responses. This review
focuses on the molecular mechanisms involved in the onset of organ-speciﬁc autoimmune diseases.
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Human immune cells normally attack exogenous bacteria or
viruses, and do not harm the body’s own cells or tissues. However,
abnormalities in immune cells can result in cell or tissue damage.
A variety of organs and tissues, including the pancreas, salivary
glands, and joints, are targets of autoimmune diseases. However, it
is not known as to why these structures are particularly vulnerable.
Sjo¨gren’s syndrome (SS) in humans is an organ-speciﬁc autoim-
mune disease characterized by lymphocytic inﬁltration into the
salivary and lacrimal glands (Fig. 1), resulting in dry mouth and dry
eyes due to deﬁcient secretion of saliva and tears [1,2]. Funda-
mental treatments for SS have not yet been established. It is
essential to study and deﬁne the molecular pathogenesis of SS, inciation for Oral Biology. Publishedorder to develop therapeutic methods that can eliminate the
underlying causes of this disease, and improve the health of
patients suffering from SS. In this review, we describe the following
features: (1) useful animal models for SS, (2) an association
between autoimmunity and defects of central tolerance in the
thymus, (3) the inﬂuence of environmental hormones on autoim-
munity, (4) the protective function of regulatory T cells in the target
organ, and (5) the critical role of estrogen in SS.2. Animal models of Sjo¨gren’s syndrome
Animal models are useful for providing an insight into the
pathogenesis or mechanisms of human autoimmune diseases.
A variety of animal models have been reported for SS. The
New Zealand black/New Zealand white (NZB/NZW) F1 mouse strain
was one of the ﬁrst models of spontaneous SS [3]. Animals in which
autoimmune diseases have naturally appeared have been studied,by Elsevier B.V. All rights reserved.
Fig. 1. Autoimmune lesion in the salivary gland tissue of a Sjo¨gren’s syndrome
patient. A histopathological photo of salivary gland tissue from a Sjo¨gren’s
syndrome patient is shown. A severe inﬂammatory lesion with destruction of
salivary gland cells is observed.
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Examples include the NOD mouse model for autoimmune (type 1)
diabetes; and the rheumatoid arthritis (RA) and systemic lupus
erythematosus (SLE) [4,5] models from the MRL/lpr mouse bearing a
Fas gene mutation. The alymphoplasia (aly/aly) mouse strain bear-
ing a mutation of the NF-kB-inducing kinase (NIK) gene has been
reported as a SS model [6]. In addition, several well-known drug and
operation-induced SS models exist. Among these, the autoimmune
model in multi-organs, which includes SS-like lesions formed by
injecting a neutralizing antibody against the CD25 molecule, was
reported in association with the deletion of regulatory T cells in the
periphery [7]. Furthermore, neonatal thymectomy of NFS/sld mice is
known to produce a model of primary SS [8]. Using this model, we
have detected a salivary gland-speciﬁc autoantigen for SS, and the
antigen-speciﬁc response of T-helper 1 (Th1) cells [9]. We have also
deﬁned the breakdown of peripheral tolerance due to the dysfunc-
tion of activation-induced cell death (AICD), which is a mechanism
for removing autoreactive T cells in the periphery [10].
A number of genetically manipulated animal models, such as
gene knockout (KO) and transgenic (TG) mice, have been used to
elucidate the molecular pathogenesis of SS. Cytokine gene-manipu-
lated animals such as TGF-b1 KO, IL-10 TG, and IL-14a TG mice have
been reported as spontaneous SS models [11–13]. Further, SS-like
lesions have been observed in some KO mice deﬁcient in auto-
immune regulator (AIRE), which is a transcription factor important
for autoantigen expression in the thymus, and in mice deﬁcient in
CCR7, a chemokine receptor for CCL19 and CCL21 that plays a
crucial role in T cell selection in the thymic medulla [14,15].
Recently, we established a retinoblastoma-associated protein 48
(RbAp48) TG mouse as a SS model in which transgenic expression
of RbAp48 in the salivary and lacrimal glands resulted in the
development of autoimmune exocrinopathy resembling SS [16].
These studies, encompassing several different SS models, provide
insight into the pathogenesis of SS and the molecular mechanisms
for central and peripheral T cell tolerance in the immune system.3. Central tolerance and organ-speciﬁc autoimmunity
SS is generally considered to be a T cell-mediated autoimmune
disorder in the salivary and lacrimal glands. We previously estab-
lished a murine model for SS in a NFS/sld mutant mouse that was
thymectomized 3 days after birth [8]. Neonatal thymectomy incertain mouse strains results in spontaneous development of inﬂam-
matory lesions resembling human autoimmune diseases in the
thyroid gland, ovaries, kidneys, testes, and stomach [17–20]. The
precise mechanisms that lead to autoimmune induction remain
unclear. In the thymus, T cell precursors that react against self-
antigens with high afﬁnity are removed by negative selection [21].
Negative selection is a crucial self-tolerance mechanism that helps
protect the body against autoimmunity. Therefore, T cell differen-
tiation in the neonatal thymus could be important for immunolo-
gical tolerance in the human body.
The transcription factor AIRE is a well-known key factor in
negative selection and organ-speciﬁc autoimmune diseases such
as SS [22]. In the thymic medulla, medullary thymic epithelial
cells (mTECs) express numerous tissue-speciﬁc self-antigens
(TSAs) in the systemic tissues [23]. AIRE-regulated expression of
TSAs is believed to promote tolerance by driving the negative
selection of self-reactive thymocytes [23]. Humans deﬁcient in
AIRE develop autoimmune polyendocrinopathy syndrome type 1
(APS1), which is characterized by autoimmune-mediated destruc-
tion of multiple organs [24]. Regulation of TSA expression in the
thymus by AIRE plays a key role in the onset of organ-speciﬁc
autoimmune diseases [23]. However, it is not clear how speciﬁc
organs are targeted in autoimmune responses.4. The inﬂuence of environmental hormones on
autoimmunity
Environmental contaminants have been shown to instigate
various biological responses, including immunological, reproduc-
tive, and neurobehavioral reactions [25]. However, effects of
environmental contaminants on autoimmunity in autoimmune
animal models have not been demonstrated. To address this
information gap, we utilized an autoimmune animal model to
study the effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
on autoimmunity. TCDD has been shown to inﬂuence immune
responses in mice [26]. Neonatal exposure of NFS/sld mice that
did not undergo thymectomy to a low-dose of TCDD resulted in
the formation of autoimmune lesions in salivary glands, followed
by inﬁltration of inﬂammatory cells into other organs [27].
Disruption of thymic selection was observed in TCDD-adminis-
tered mice [27]. The endogenous expression of aryl hydrocarbon
receptor (AhR) in the neonatal thymus was signiﬁcantly higher
than that in the adult thymus, suggesting that the neonatal
thymus could be much more sensitive to TCDD [27]. In addition,
TCDD-exposed mice had signiﬁcantly higher levels of Th1 cyto-
kines (e.g., IL-2 and IFN-g) in the peripheral CD4þ T cells, and
autoantibodies relevant for SS in the sera, compared with control
mice [27]. mRNA expression of AIRE and TSAs, such as salivary
protein-1 (SP-1) and GAD67, in the thymus were reduced by
in vivo neonatal exposure of SS model mice to low-dose TCDD
[27]. These ﬁndings indicate that TCDD may inﬂuence the selec-
tion of autoreactive T cells in the thymus via AIRE. TCDD/AhR
signaling in the neonatal thymus appears to play an important
role in early thymic differentiation related to autoimmunity.5. The critical role of regulatory T cells in the target organ
Regulatory T cells (Treg cells) are a unique subset of T cells that
play a critical role in maintaining immunotolerance [28]. The
expression of the transcription factor forkhead box p3 (Foxp3) is
the genetic hallmark of Treg cells [29]. Autoimmune lesions are
observed in the lacrimal and salivary glands in C-C-chemokine
receptor 7 (CCR7)-deﬁcient mice, similar to those observed in SS
[15]. In addition, enhanced immunity in CCR7 KO mice is caused
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[30]. Previously, we reported that CCR7 governs the patrolling
functions of Treg cells by controlling their migration to target
organs, thereby maintaining autoimmunity [31]. Moreover, we
found that the migratory function of CCRKO Treg cells was
impaired in response to sphingosine 1-phosphate (S1P), suggest-
ing that CCR7 participates in the molecular mechanism under-
lying the migratory function of peripheral Treg cells through S1P
and one of its receptors, S1P1 [31]. Recently, we demonstrated
that impaired migratory response of CCRKO Treg cells to S1P
occurred because of defective association of S1P1 with a G
protein-coupled receptor (Fig. 2). Additionally, T-cell receptor
(TCR)- and S1P1-mediated Ras-related C3 cotulinum toxin sub-
strate 1 (Rac-1), extracellular signal-related kinase (ERK), and
c-Jun phosphorylation required for activator protein 1 (AP-1)
transcriptional activity were signiﬁcantly impaired in CCR7KO
Treg cells [32] (Fig. 2). We also detected abnormal nuclear
localization of Foxp3 after abrogation of c-Jun and Foxp3 inter-
action in the nucleus of CCR7KO Treg cells [32]. These results
indicate that CCR7 controls the migratory function of Treg cells
through S1P1-mediated AP-1 signaling, which is regulated
through the interaction of CCR7 with Foxp3 in the nucleus,
thereby protecting the body from autoimmunity. Characterization
of this cellular and molecular mechanism has signiﬁcant clinical
implications that would support the development of new diag-
nostic and therapeutic approaches for organ-speciﬁc autoimmune
diseases such as SS, and that would clarify the processes by which
autoimmunity is regulated by the local immune system.6. Pathogenesis of Sjo¨gren’s syndrome based on hormonal
imbalance
Although several autoimmune diseases are known to develop
in postmenopausal women, the mechanisms by which estrogen
deﬁciency inﬂuences autoimmunity remain unclear. It has been
suggested that estrogenic action is responsible for the strongS1P1
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Fig. 2. A possible molecular mechanism of Treg cell function mediated by CCR7.
When S1P binds to S1P1, the S1P/S1P1 complex is internalized in the cell
membrane. The cooperative action of CCR7 with TCR/CD3 controls the internaliza-
tion of S1P/S1P1 with Gi after the phosphorylation of c-Jun as well as MAPK
activation in Treg cells.female preponderance of many autoimmune diseases, including
SLE, RA, and SS [33]. Recent evidence suggests that apoptosis plays a
key role in the physiology and pathogenesis of various autoimmune
diseases [34]. We have reported that estrogenic action inﬂuences
target epithelial cells through Fas-mediated apoptosis in a murine
model [35]. We previously found that spontaneous tissue-speciﬁc
apoptosis in the exocrine glands that occurs in estrogen-deﬁcient
mice may contribute to the development of autoimmune exocrino-
pathy [36]. In the quest to understand the role of estrogen deﬁciency
in the development of autoimmunity, we identiﬁed the retinoblas-
toma-associated protein 48 (RbAp48) gene speciﬁc for estrogen
deﬁciency-dependent apoptosis in the exocrine glands, using trans-
genic mice. The mice expressed the RbAp48 gene, which induced
tissue-speciﬁc apoptosis in the glands [36]. Speciﬁcally, human
salivary gland (HSG) cells were stimulated with tamoxifen, an
estrogen receptor antagonist, to inhibit estrogen signaling. We
detected several tamoxifen-induced genes by differential display
analysis, using mRNA from HSG cells stimulated with and without
tamoxifen. We focused on RbAp48 based on its expression pattern,
function, and its association with cell survival and death. RbAp48 is
known to be a regulatory molecule for the cell cycle via retinoblas-
toma protein (RB). We observed salivary gland cell-speciﬁc apopto-
sis, in contrast to various cell lines originating from other organs,
including the liver, kidney, lymphocyte, and mammary gland. Thus,
we identiﬁed RBAp48 as the key molecule controlling apoptosis of
salivary gland cells via estrogen deﬁciency [36]. Transgenic expres-
sion of RbAp48 resulted in the development of autoimmune
exocrinopathy resembling SS [16]. CD4þ T cell-mediated autoim-
mune lesions aggravated with age in association with autoantibody
production [16]. Moreover, we found that the salivary and lacrimal
epithelial cells can produce interferon-g (IFN-g) in addition to
interleukin-18, which activates IFN regulatory factor-1 and class II
transactivator (CIITA) [16]. These results indicate a novel immuno-
competent role for RbAp48-expressing epithelial cells that can
produce IFN-g (Fig. 3), resulting in loss of local tolerance before
the development of gender-based autoimmunity.Fig. 3. Expression of RbAp48 and IFN-g in salivary epithelial cells of a Sjo¨gren’s
syndrome patient. Confocal analysis shows that expression of RbAp48 (Alexa-488:
green) and IFN-g (Alexa-568: red) is observed in the frozen section of salivary
gland tissue from an SS patient. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 4. Autoimmunity is a multi-factorial disease. Autoimmune diseases occur as a
result of multiple factors, including genetic, epigenetic and environmental vari-
ables, sex hormones, and stress. The breakdown of central, peripheral, and local
tolerance triggers the onset of organ-speciﬁc autoimmune disease.
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Recent studies of animal models and SS patients suggest that
the complicated interplay among multiple factors, including
genetic and environmental variables, breakdown of immunologi-
cal tolerance, and hormone imbalance, inﬂuences cellular and
hormonal autoimmunity against target organs (Fig. 4). Any
dysfunction or impairment of the exocrine gland may precede
autoimmunity in the pathogenesis of SS. Further elucidation of
the molecular mechanisms of autoimmune diseases, in terms of
both the immune system and the targeting of speciﬁc organs, is
essential to understanding the pathogenesis of autoimmunity,
and to lead to the development of new diagnostic and therapeutic
approaches for SS.Conﬂict of interest
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